In brief

BMJ 2002; 324 doi: (Published 27 April 2002) Cite this as: BMJ 2002;324:994

FDA demands warning label on rofecoxib: The US Food and Drug Administration has ordered drug manufacturer Merck to put a warning label on the cyclo-oxygenase-2 (COX-2) inhibitor rofecoxib (Vioxx) stating that it can raise blood pressure and may increase the risk of heart attacks; the move follows research findings on the drug's side effects (BMJ 2001;323:471).

Physicians …

View Full Text

Log in

Log in through your institution


* For online subscription